CN111040945A - 一种多种类干细胞培养皿及其培养基 - Google Patents
一种多种类干细胞培养皿及其培养基 Download PDFInfo
- Publication number
- CN111040945A CN111040945A CN201911397218.4A CN201911397218A CN111040945A CN 111040945 A CN111040945 A CN 111040945A CN 201911397218 A CN201911397218 A CN 201911397218A CN 111040945 A CN111040945 A CN 111040945A
- Authority
- CN
- China
- Prior art keywords
- parts
- stem cell
- growth factor
- culture dish
- cell culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 34
- 239000001963 growth medium Substances 0.000 title claims abstract description 16
- 238000004113 cell culture Methods 0.000 title claims abstract description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims abstract description 24
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims abstract description 24
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 24
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 24
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims abstract description 24
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 12
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims abstract description 12
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims abstract description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract description 12
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 12
- 102000003951 Erythropoietin Human genes 0.000 claims abstract description 12
- 108090000394 Erythropoietin Proteins 0.000 claims abstract description 12
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract description 12
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 12
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 12
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 12
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 12
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 12
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 102000004338 Transferrin Human genes 0.000 claims abstract description 12
- 108090000901 Transferrin Proteins 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- 229960005305 adenosine Drugs 0.000 claims abstract description 12
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims abstract description 12
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims abstract description 12
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 12
- 229940105423 erythropoietin Drugs 0.000 claims abstract description 12
- 102000013361 fetuin Human genes 0.000 claims abstract description 12
- 108060002885 fetuin Proteins 0.000 claims abstract description 12
- 229940029575 guanosine Drugs 0.000 claims abstract description 12
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 12
- 229960003987 melatonin Drugs 0.000 claims abstract description 12
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 12
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940113082 thymine Drugs 0.000 claims abstract description 12
- 239000012581 transferrin Substances 0.000 claims abstract description 12
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940045145 uridine Drugs 0.000 claims abstract description 12
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- 239000006143 cell culture medium Substances 0.000 claims abstract description 7
- 238000005192 partition Methods 0.000 claims description 10
- 239000007640 basal medium Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 210000002444 unipotent stem cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/34—Internal compartments or partitions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/54—Constructional details, e.g. recesses, hinges hand portable
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Abstract
本发明发明一种多种类干细胞培养皿及其培养基，包括培养皿体，所述培养皿体内设有培养槽，培养皿体内壁设有轴向阵列分布的第一卡槽，培养槽中心位置设有中心柱，中心柱上设有轴向阵列分布的棱条，棱条之间形成轴向阵列分布的第二卡槽，培养槽内设有分隔器，一种多种类干细胞培养基,包括以下成分组成重组转铁蛋白3份、纤维连接蛋白8份、胎球蛋白3份、基础培养基18份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C 10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、促红素0.2份与褪黑素0.005份。本发明结构简单，易于使用，便于根据不同情况进行调整培养不同种类的干细胞。
Description
技术领域
本发明涉及一种干细胞培养领域，具体是一种多种类干细胞培养皿及其培养基。
背景技术
干细胞是一类具有自我复制能力的多潜能细胞。在一定条件下，它可以分化成多种功能细胞。根据干细胞所处的发育阶段分为胚胎干细胞和成体干细胞。根据干细胞的发育潜能分为三类：全能干细胞、多能干细胞和单能干细胞。干细胞是一种未充分分化，尚不成熟的细胞，具有再生各种组织器官和人体的潜在功能，医学界称为“万用细胞”，现提出一种多种类干细胞培养皿及其培养基，便于根据不同情况进行调整培养不同种类的干细胞，便于区分，并且节约培养设备。
发明内容
本发明的目的在于提供一种多种类干细胞培养皿及其培养基，结构简单，易于使用，便于根据不同情况进行调整培养不同种类的干细胞，节约是培养设备，提高了培养成活率，降低了培养干细胞的设备成本。
本发明的目的可以通过以下技术方案实现：
一种多种类干细胞培养皿，包括培养皿体，所述培养皿体内设有培养槽，培养皿体内壁设有轴向阵列分布的第一卡槽，培养槽中心位置设有中心柱，中心柱上设有轴向阵列分布的棱条，棱条之间形成轴向阵列分布的第二卡槽，培养槽内设有分隔器，中心柱槽四周还形成轴向阵列分布的棱条槽，分隔器上端设有环形提手。
进一步地，所述分隔器下端设有轴向阵列分布的第一分隔板，第一分隔板顶端形成中心柱槽。
进一步地，所述中心柱槽形状与中心柱相同。
进一步地，所述培养槽内还设有轴向阵列分布的若干第二分隔板，第二分隔板上端设有把手。
一种多种类干细胞培养基，包括以下成分组成：重组转铁蛋白1～5份、纤维连接蛋白5～10份、胎球蛋白1～5份、基础培养基15～20份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、、促红素0.2份与褪黑素0.005份。
进一步地，包括以下成分组成：重组转铁蛋白1份、纤维连接蛋白5份、胎球蛋白1份、基础培养基15份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、促红素0.2份与褪黑素0.005份。
进一步地，包括以下成分组成重组转铁蛋白3份、纤维连接蛋白8份、胎球蛋白3份、基础培养基18份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、、促红素0.2份与褪黑素0.005份。
本发明的有益效果：
1、本发明结构简单，易于使用，便于根据不同情况进行调整培养不同种类的干细胞；
2、本发明节约是培养设备，提高了培养成活率，降低了培养干细胞的设备成本。
附图说明
下面结合附图对本发明作进一步的说明。
图1是本发明多种类干细胞培养皿结构示意图；
图2是本发明多种类干细胞培养皿及其培养基部分结构示意图；
图3是本发明多种类干细胞培养皿及其培养基爆炸结构示意图。
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例，都属于本发明保护的范围。
在本发明的描述中，需要理解的是，术语“开孔”、“上”、“下”、“厚度”、“顶”、“中”、“长度”、“内”、“四周”等指示方位或位置关系，仅是为了便于描述本发明和简化描述，而不是指示或暗示所指的组件或元件必须具有特定的方位，以特定的方位构造和操作，因此不能理解为对本发明的限制。
一种多种类干细胞培养皿，包括培养皿体1，如图1、图2、图3所示，培养皿体1内设有培养槽11，培养皿体1内壁设有轴向阵列分布的第一卡槽12，培养槽11中心位置设有中心柱2，中心柱2上设有轴向阵列分布的棱条21，棱条21之间形成轴向阵列分布的第二卡槽22，培养槽11内设有分隔器3，分隔器3下端设有轴向阵列分布的第一分隔板32，第一分隔板32顶端形成中心柱槽33，中心柱槽33形状与中心柱2相同，中心柱槽33四周还形成轴向阵列分布的棱条槽34，分隔器3上端设有环形提手31，培养槽11内还设有轴向阵列分布的若干第二分隔板4，第二分隔板4上端设有把手41。
一种多种类干细胞培养基，包括以下成分组成：
重组转铁蛋白1～5份、纤维连接蛋白5～10份、胎球蛋白1～5份、基础培养基15～20份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、、促红素0.2份与褪黑素0.005份。
实施例1
使用分隔器3将培养皿体1分隔为等大小的间隔，将每格放入重组转铁蛋白1份、纤维连接蛋白5份、胎球蛋白1份、基础培养基15份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、促红素0.2份与褪黑素0.005份调配的培养基。
实施例2
使用分隔器3将培养皿体1分隔为等大小的间隔，将每格放入重组转铁蛋白3份、纤维连接蛋白8份、胎球蛋白3份、基础培养基18份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、、促红素0.2份与褪黑素0.005份。
实施例3
使用第二分隔板4，将培养皿体1分成需要的份数，将每格放入重组转铁蛋白3份、纤维连接蛋白8份、胎球蛋白3份、基础培养基18份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、、促红素0.2份与褪黑素0.005份。
实施例4
使用第二分隔板4，将培养皿体1分成需要的份数，将每格放入重组转铁蛋白1份、纤维连接蛋白5份、胎球蛋白1份、基础培养基15份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、促红素0.2份与褪黑素0.005份调配的培养基。
在本说明书的描述中，参考术语“一个实施例”、“示例”、“具体示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中，对上述术语的示意性表述不一定指的是相同的实施例或示例。而且，描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
以上显示和描述了本发明的基本原理、主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。
Claims (7)
1.一种多种类干细胞培养皿，包括培养皿体(1)，其特征在于，所述培养皿体(1)内设有培养槽(11)，培养皿体(1)内壁设有轴向阵列分布的第一卡槽(12)，培养槽(11)中心位置设有中心柱(2)，中心柱(2)上设有轴向阵列分布的棱条(21)，棱条(21)之间形成轴向阵列分布的第二卡槽(22)，培养槽(11)内设有分隔器(3)，中心柱槽(33)四周还形成轴向阵列分布的棱条槽(34)，分隔器(3)上端设有环形提手(31)。
2.根据权利要求1所述的一种多种类干细胞培养皿,其特征在于，所述分隔器(3)下端设有轴向阵列分布的第一分隔板(32)，第一分隔板(32)顶端形成中心柱槽(33)。
3.根据权利要求1所述的一种多种类干细胞培养皿,其特征在于，所述中心柱槽(33)形状与中心柱(2)相同。
4.根据权利要求1所述的一种多种类干细胞培养皿,其特征在于，所述培养槽(11)内还设有轴向阵列分布的若干第二分隔板(4)，第二分隔板(4)上端设有把手(41)。
5.一种多种类干细胞培养基，其特征在于，包括以下成分组成：重组转铁蛋白1～5份、纤维连接蛋白5～10份、胎球蛋白1～5份、基础培养基15～20份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、、促红素0.2份与褪黑素0.005份。
6.根据权利要求5所述的一种多种类干细胞培养基,其特征在于，包括以下成分组成：重组转铁蛋白1份、纤维连接蛋白5份、胎球蛋白1份、基础培养基15份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、促红素0.2份与褪黑素0.005份。
7.根据权利要求5所述的一种多种类干细胞培养基,其特征在于，包括以下成分组成重组转铁蛋白3份、纤维连接蛋白8份、胎球蛋白3份、基础培养基18份、人血白蛋白5份、腺苷10份、胞苷10份、鸟苷10份、尿苷10份、胸腺嘧啶10份、氢化可的松10份、维生素C10份、碱性成纤维细胞生长因子0.02份、表皮生长因子0.02份、、促红素0.2份与褪黑素0.005份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911397218.4A CN111040945A (zh) | 2019-12-30 | 2019-12-30 | 一种多种类干细胞培养皿及其培养基 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911397218.4A CN111040945A (zh) | 2019-12-30 | 2019-12-30 | 一种多种类干细胞培养皿及其培养基 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111040945A true CN111040945A (zh) | 2020-04-21 |
Family
ID=70241682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911397218.4A Pending CN111040945A (zh) | 2019-12-30 | 2019-12-30 | 一种多种类干细胞培养皿及其培养基 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111040945A (zh) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008009641A1 (en) * | 2006-07-17 | 2008-01-24 | Novozymes A/S | Cell culture media |
| WO2014094386A1 (zh) * | 2012-12-20 | 2014-06-26 | 上海市第十人民医院 | 一种干细胞培养基及其应用和干细胞培养方法 |
| CN104877961A (zh) * | 2015-04-15 | 2015-09-02 | 广州赛莱拉干细胞科技股份有限公司 | 一种无血清的人羊膜间充质干细胞培养基及其制备方法 |
| CN204714797U (zh) * | 2015-04-21 | 2015-10-21 | 北京青藤谷禧干细胞科技研究院有限公司 | 一种培养皿 |
| CN205188305U (zh) * | 2015-10-22 | 2016-04-27 | 深圳爱生再生医学科技有限公司 | 细胞共培养的培养皿 |
| CN207418717U (zh) * | 2017-11-09 | 2018-05-29 | 四川农业大学 | 一种微生物分隔培养板 |
| CN208829663U (zh) * | 2018-08-17 | 2019-05-07 | 南方医科大学深圳医院 | 一种新型干细胞培养皿 |
| CN110305839A (zh) * | 2019-08-02 | 2019-10-08 | 陕西佰傲干细胞再生医学有限公司 | 间充质干细胞无血清培养基 |
-
2019
- 2019-12-30 CN CN201911397218.4A patent/CN111040945A/zh active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008009641A1 (en) * | 2006-07-17 | 2008-01-24 | Novozymes A/S | Cell culture media |
| WO2014094386A1 (zh) * | 2012-12-20 | 2014-06-26 | 上海市第十人民医院 | 一种干细胞培养基及其应用和干细胞培养方法 |
| CN104877961A (zh) * | 2015-04-15 | 2015-09-02 | 广州赛莱拉干细胞科技股份有限公司 | 一种无血清的人羊膜间充质干细胞培养基及其制备方法 |
| CN204714797U (zh) * | 2015-04-21 | 2015-10-21 | 北京青藤谷禧干细胞科技研究院有限公司 | 一种培养皿 |
| CN205188305U (zh) * | 2015-10-22 | 2016-04-27 | 深圳爱生再生医学科技有限公司 | 细胞共培养的培养皿 |
| CN207418717U (zh) * | 2017-11-09 | 2018-05-29 | 四川农业大学 | 一种微生物分隔培养板 |
| CN208829663U (zh) * | 2018-08-17 | 2019-05-07 | 南方医科大学深圳医院 | 一种新型干细胞培养皿 |
| CN110305839A (zh) * | 2019-08-02 | 2019-10-08 | 陕西佰傲干细胞再生医学有限公司 | 间充质干细胞无血清培养基 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0703978T3 (da) | Medium til langtidsproliferation og -udvikling af celler | |
| DE60036470D1 (de) | Untereinheiten von myeloid-progenitorzellen von säugern | |
| CN108949678B (zh) | 一种干细胞培养基及培养方法 | |
| WO2002072762A3 (en) | Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture | |
| WO2012032521A3 (en) | Novel methods and culture media for culturing pluripotent stem cells | |
| WO2003014313A3 (en) | Alternative compositions and methods for the culture of stem cells | |
| CN111040945A (zh) | 一种多种类干细胞培养皿及其培养基 | |
| Nakahata et al. | Single-cell origin of human mixed hemopoietic colonies expressing various combinations of cell lineages | |
| CA2324479A1 (en) | Immortalised cell line derived from normal human skin tissues | |
| CN202945247U (zh) | 具有单培养、共培养及群培养优势的人胚胎培养皿 | |
| Macieira-Coelho et al. | The transition from primary culture to spontaneous immortalization in mouse fibroblast populations | |
| Carè et al. | c-fes expression in ontogenetic development and hematopoietic differentiation | |
| CN108220231A (zh) | 一种干细胞培养基及其制备方法和应用 | |
| US5371010A (en) | Method for growing eukaryotic cells using soft agar assay and kit | |
| DE69230879D1 (de) | Verwendung von Hepatocyten-Wachstumsfaktoren zur Herstellung eines Vermehrungssystems für Hematopoietische Stammzellen | |
| Tian et al. | Karyotyping, immunophenotyping, and apoptosis analyses on human hematopoietic precursor cells derived from umbilical cord blood following long-term ex vivo expansion | |
| Wright et al. | Haemopoietic tissue | |
| Tsuji et al. | Stochastic model for multipotent hemopoietic progenitor differentiation | |
| CN208008824U (zh) | 细胞培养板 | |
| Xiong et al. | Ex vivo expansion of human umbilical cord blood hematopoietic progenitor cells in a novel three-dimensional culture system | |
| Kidder | Simultaneous derivation of embryonic and trophoblast stem cells from mouse blastocysts | |
| CN205258452U (zh) | 一种新型精子上游试管架 | |
| CN217265789U (zh) | 一种脂肪间充质干细胞培养皿放置架 | |
| CN217047326U (zh) | 一种单元体热流道系统 | |
| Liu et al. | Cell cycle negative regulator p16 induces senescence-like alterations in human fibroblasts (2BS) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200421 |